New Freeze-Dried rabies vaccine aims to save lives in High-Risk regions

NCT ID NCT07672626

Completed ⭐️ VACCINE ⭐️ Sponsor: Jiangsu Province Centers for Disease Control and Prevention Source: ClinicalTrials.gov ↗

First seen Jun 29, 2026 · Last updated Jun 30, 2026 · Updated 1 time

Summary

This phase 3 trial tests a freeze-dried rabies vaccine in healthy Chinese volunteers aged 10 to 60. The study compares the new vaccine's ability to trigger protective antibodies and its safety against an existing rabies vaccine. Rabies is nearly always fatal once symptoms appear, so effective vaccines are critical for prevention.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: freeze-dried human rabies vaccine (Vero cell)
What this could lead to: If successful, this could provide a safe and effective rabies vaccine option for large-scale use, potentially saving lives in regions where rabies is a threat.
What could go wrong: This is a phase 3 trial, but results may not generalize beyond the Chinese population studied. The vaccine may not prove non-inferior to the control, or rare side effects could emerge.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for VACCINE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

rabies prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

VACCINE

Contacts and locations

Locations

Pizhou county Center for Disease Control and Prevention

Pizhou, Jiangsu, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.